Gold prices steady ahead of Fed decision; weekly weakness noted
Investing.com -- Investment firm KKR is set to increase its stake in Henry Schein (NASDAQ:HSIC), a provider of health care solutions. The firm plans to invest an additional $250 million in Henry Schein common stock, according to a recent statement. This move will expand KKR’s current holdings in the company.
In addition to the increased investment, two representatives from KKR will join the Henry Schein board as independent directors. The new directors are expected to provide strategic guidance and oversight to the company.
Henry Schein has also announced an expansion of its share repurchase program. The company has authorized an additional $500 million for this initiative. This move indicates the company’s confidence in its own stock and its commitment to delivering shareholder value.
In other financial news, Henry Schein has released preliminary unaudited results for the fourth quarter of 2024. The company reported a GAAP diluted EPS of $0.74 and a non-GAAP diluted EPS of $1.19. However, the adjusted EPS of $1.19 fell slightly short of the estimated $1.23.
Looking ahead to 2025, Henry Schein is targeting a low to mid single digit growth for its non-GAAP EPS. Furthermore, the company expects its adjusted EBITDA to grow in a mid-single digit range in 2025, compared to 2024. These targets reflect the company’s positive outlook and its commitment to sustained growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.